Development of a Novel Medium Throughput Flow-Cytometry Based

2	Micro-Neutralisation Test for SARS-CoV-2 with Applications in
3	Clinical Vaccine Trials and Antibody Screening
4	Sophie O'Reilly ¹ , Grace Kenny ^{1,2} , Tamara Alrawahneh ¹ , Nathan Francois ¹ , Matthew Angeliadis ¹ ,
5	Valentin de Masson d'Autume ¹ , Alejandro Garcia Leon ¹ , Eoin R. Feeney ^{1,2} , Obada Yousif ³ , Aoife
6	Cotter ^{1,4} , Eoghan de Barra ^{5,6} Mary Horgan ⁷ , Patrick WG Mallon ^{1,2} , Virginie Gautier ¹
7	¹ Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4,

- 8 Ireland
- 9 ²Department of Infectious Diseases, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland
- 10 ³Endocrinology Department, Wexford General Hospital, Carricklawn, Wexford, Ireland
- 11 ⁴Department of Infectious Diseases, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland
- 12 ⁵Department of Infectious Diseases, Beaumont Hospital, Beaumont, Dublin 9, Ireland
- 13 ⁶Department of International Health and Tropical Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
- 14 ⁷Department of Infectious Diseases, Cork University Hospital, Wilton, Co Cork, Ireland
- 15 Corresponding Author: Virginie Gautier Virginie.gautier@ucd.ie
- 16

1

- 17
- 18
- 19

- 20
- 21

22



NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract

25 Quantifying neutralising capacity of circulating SARS-COV-2 antibodies is critical in evaluating 26 protective humoral immune responses generated post-infection/post-vaccination. Here we describe a 27 novel medium-throughput flow cytometry-based micro-neutralisation test to evaluate Neutralising Antibody (NAb) responses against live SARS-CoV-2 Wild Type and Variants of Concern (VOC) in 28 29 convalescent/vaccinated populations. Flow Cytometry-Based Micro-Neutralisation Test (Micro-NT) was performed in 96-well plates using clinical isolates WT-B, WT-B.177.18 and/or VOCs Beta and 30 Omicron. Plasma samples (All Ireland Infectious Diseases (AIID) Cohort) were serially diluted (8 31 points, half-log) from 1/20 and pre-incubated with SARS-CoV-2 (1h, 37°C). Virus-plasma mixture 32 were added onto VERO E6/VERO E6 TMPRSS2 cells for 18h. Percentage infected cells was analysed 33 34 by automated flow cytometry following trypsinisation, fixation and SARS-CoV-2 Nucleoprotein intracellular staining. Half-maximal Neutralisation Titres (NT50) were determined using four-35 parameter logistic regression. Our assay was compared to Plaque Reduction Neutralisation Test (PRNT) 36 37 and validated against WHO anti-SARS-CoV-2 Immunoglobulin Standards. Using WHO Standards with 38 low, medium or high anti-SARS-CoV-2 IgG, both Micro-NT and PRNT achieved comparable NT50 values. Micro-NT was found to be highly reproducible (inter-assay CV of 11.64%). Screening 190 39 convalescent samples and 11 COVID-19 naive controls (AIID cohort) we demonstrated that Micro-NT 40 41 has broad dynamic range differentiating NT50s <1/20 to >1/5000. We could also characterise immune-42 escape VOC observing up to 10-fold reduction in NT50 against SARS-CoV-2 Beta variant. Our flow 43 cytometry-based Micro-NT is a robust and reliable assay to quantify NAb titres, and has been selected 44 as an endpoint in clinical trials. It has higher throughput (96 well format versus 12 well) and reduced 45 infection time (18h vs 48-96h) compared to the gold standard PRNT.

46 Abbreviations

- 47 S=Spike, NP=Nucleoprotein, NAbs= Neutralising Antibodies, RBD=Receptor Binding Domain, ACE-
- 48 2=Angiotensin-Converting Enzyme 2, WT=Wild-Type, VOC=Variant of Concern, PRNT=Plaque
- 49 Reduction Neutralisation Test, CPE=Cytopathic Effects, NT50=50% Neutralisation Titre.

Introduction 50

- 51 SARS-CoV-2 is the viral agent responsible for the Coronavirus Infectious Disease 2019 (COVID-19) pandemic (1). The disease was given pandemic status by the World Health Organisation in March
- 52
- 2020, and as of August 2022, there has been 600 million cases, and 6.5 million deaths (2). 53

54 Both T-cell and humoral immune responses are required for protection from COVID-19. Humoral 55 immunity relies on B cell exposure to SARS-CoV-2 antigens, which triggers their proliferation into 56 antibody secreting plasma cells (3). Following infection, antibodies are produced against SARS-CoV-57 2 viral proteins, predominantly the Spike (S) and the Nucleocapsid Protein (NP) (4, 5). Neutralising 58 antibodies (NAbs) are a subset of SARS-CoV-2 antibodies that prevent viral entry, through either direct 59 blocking of virus binding to the host cell receptor, or preventing conformational changes required for 60 membranes fusion. SARS-CoV-2 NAbs target the S protein, making it the preferred COVID-19 vaccine candidate (6, 7). 61

62 The S protein is comprised of trimeric S1/S2 heterodimers. S1, harbouring an N-terminal domain and a Receptor Binding Domain (RBD), interacts with the host cell through binding of the RBD to the 63 64 angiotensin-converting enzyme 2 (ACE-2) receptor. Following S1/S2 cleavage by host cell proteases including furin, S2' cleavage by TMPRSS2 or Cathepsin-L mediates membrane fusion and cell entry 65 (8). The most potent NAbs target the RBD as these directly compete with ACE-2 for binding. Mutations 66 67 in this site are often associated with immune escape (9). Non-RBD sites are more evolutionarily 68 conserved, so NAbs targeting these sites can often maintain efficacy against SARS-CoV-2 variants as 69 well as display cross-reactivity with other sarbecoviruses (10).

70 An effective antibody response provides protection against COVID-19. 'The Protective Neutralisation 71 Classification Model' described by (6) suggests that the protective neutralisation titre (reducing risk of 72 infection by 50%) is 20% of the mean neutralisation titre of a convalescent cohort, which they have found to strongly predict protective immunity (against symptomatic disease) elicited by COVID-19 73 74 vaccine trials, while achieving a titre of only 3% of the mean is sufficient to reduce risk of severe disease 75 by 50%.

76 Not all S-targeting antibodies are neutralising. Post-infection or post-vaccination, a polyclonal antibody population is produced, targeting sites along the S protein (11). Some may only bind, but not have any 77 neutralising capacity due to their site of action. Others may offer protection against Wild-type (WT) 78 79 SARS-CoV-2, the strain against which the vaccine S is modelled, but not against immune-escape 80 Variants of Concern (VOC), including Beta and Omicron, which have amino acid mutations in key 81 antibody binding sites in the RBD (12). For this reason, an antibody titre, the measure of total anti-82 SARS-CoV-2 IgGs against a certain target present in a sample (13), is not sufficient to infer a protective 83 immune response. Instead, the functional capacity of an antibody population can be determined using a 84 neutralisation test.

Neutralisation tests, used to measure the capacity of a monoclonal antibody or plasma/serum to inhibit viral infection of susceptible cells, have proved valuable in elucidating SARS-CoV-2 antibody responses over time (14), in convalescent versus vaccinated individuals (15), and against SARS-CoV-2 VOCs (16) (17). This information is critical to forming effective public health strategies, from understanding when vaccine-induced protection wanes in different cohorts to devise booster strategies (18, 19), to identifying plasma donors for convalescent therapy (20, 21), to rapid identification of new VOCs that escape pre-existing immunity (22, 23).

92 The gold standard viral neutralisation assay is the Plaque Reduction Neutralisation Test (PRNT) (24). 93 Here, live SARS-CoV-2 is co-incubated with serially diluted antibodies to facilitate neutralisation, and the virus is then used to infect a monolayer of cells. Over days, infected cells will display viral 94 cytopathic effects (CPE) and die, leaving visible plaques in the monolayer that can be quantified to 95 determine the reduction in infectious titre associated with the dilution factor of antibodies. However, 96 97 this technique has several limitations which alternative assays have been developed to address. These include the large surface area for plaque formation requiring large wells, typically 6- or 12-well, which 98 99 limits the throughput. The time to develop visual plaques can be up to 5 days for SARS-CoV-2. 100 Furthermore, plaque counting is often done by eye, and even with automated software can be error-101 prone and subjective.

To address the low throughput, several assays have been adapted from PRNT, firstly facilitating neutralisation with a co-incubation of virus and antibodies, followed by determining the effectiveness of neutralisation through infection of susceptible cells. The key difference in these assays are the format (96-well plates) and the endpoints (Table 1). Rather than wait for visible plaques, micro-foci can be detected in the monolayer after only 18-hrs infection by staining of viral antigens (24, 25). Alternatively, recombinant SARS-CoV-2 virus expressing Green Fluorescent Protein can be detected directly without the need for further processing (25). Another approach is to detect viral genetic material in cell lysates through RT-qPCR following RNA extraction (26, 27) or to quantify replicating virus (viral load) by enzyme-linked immunosorbent assay (ELISA) (28). Other assays score the presence or absence of CPE under a microscope (29, 30) using a cell imager (31), or using colorimetric cellular dyes (29). All these assays have the advantage of being medium to high throughput, suitable for 96-well plates, and rapid compared to PRNT. However, they still have limitations. Foci-based assays can have difficulty separating spots that are close together, CPE is subjective and slow to develop, recombinant virus is time consuming to develop and validate to rapidly address new variants, and RT-qPCR is costly.

Table 1: Comparison of Micro-Neutralisation Tests.

Micro-Neutralisation Assays	Assay Endpoints	Infection time	Overlay required	Quantitative	Viral/Cellular Target	Reference
Flow Cytometry Based Micro- NT	Flow Cytometry	18-hrs	No	Yes	Intracellular SARS-CoV-2 NP	(This report)
ELISA-based virus neutralisation assay	Enzyme-linked immunosorbent assay (ELISA)	24 hrs	No	Yes	Intracellular SARS-CoV-2 NP	(28)
qRT-PCR-based virus neutralization assay	RT-qPCR	24 hrs	No	Yes	Intracellular SARS-CoV-2 genomic RNA	(26,27)
Microneutralization assay (MNA)/ Focus reduction neutralization test (FRNT)	Infected foci measured by computer-controlled imagers	22-24 hrs	Yes	Yes	Cell-membrane associated SARS-CoV-2 Spike	(24, 25)
mNeonGreen-based FRNT (FRNT-mNG)	Fluorescent ELI-SPOT	24-hrs	Yes	Yes	mNeonGreen expressing recombinant SARS-CoV-2	(25)
Virus Neutralisation Test (VNT)	CPE observed under light microscope	5 days	No	No	CPE	(30)
Colorimetric cytopathic effect- based microneutralization assay	Optical density of cellular lysate	3 days	No	Yes	CPE proxy	(29)
High-content fluorescent live SARS-CoV-2 neutralization assay	Nuclei counts using IN CELL analyser	3 days	No	Yes	CPE proxy	(31)

127

Table 1: Comparison of Micro-Neutralisation Tests. Micro-NTs are conducted in medium-throughput
formats, typically 96-well plates. Following neutralisation of live SARS-CoV-2 by serial dilutions of
plasma/serum, neutralisation capacity of each dilution is determined by corresponding infection levels
compared to controls. The primary difference is the endpoint used to quantify infection, which may
measure viral production directly, or viral cytopathic effects (CPE).

133

134 One significant limitation of PRNT, is the use of live SARS-CoV-2. This means the assays must be carried out in Containment Level 3 facilities, by highly trained staff. Pseudovirus assays, where a viral 135 136 backbone from vesicular stomatitis virus (VSV) or lentivirus, is engineered to express the SARS-CoV-137 2 S protein, have become popular choice as they only require Containment Level 2 facilities (32). 138 However, they focus on the impact of S protein independently of other SARS-CoV-2 proteins present at the viral membrane and typically only measure viral entry, while live-virus neutralisation assays can 139 140 monitor several rounds of replication. As the virus can spread cell-to-cell post-entry, it may evade 141 neutralisation, thus explaining the lower neutralisation titres observed in such assays compared to pseudovirus assay (33). Surrogate Viral Neutralisation Tests or competitive immunoassays where 142 antibodies prevent interaction between recombinant viral Spike protein and ACE-2 receptor in vitro 143 have been proposed as a user-friendly method of inferring neutralisation capacity in the absence of 144 virus, however they have shown poor correlation with PRNT (34). 145

146 Here we aimed to develop a novel neutralisation assay suitable for medium-throughput screening of SARS-CoV-2 antibodies. We chose a live virus assay, which most closely reflects in vivo neutralisation, 147 as all viral proteins are present and complete. Instead of using a CPE-based approach, we used flow 148 149 cytometry to quantify individual infected cells based on intracellular SARS-CoV-2 NP staining. This 150 assay uses a 96-well plate format, for processing of up to 36-samples per day. It does not require 151 washing the cells post-infection or adding an overlay, reducing hands-on processing time. The duration 152 of infection is only 18-hrs allowing rapid turn-around of results, and the output is quantitative (% 153 infected cells per well), less subjective than plaque or CPE-based assays.

This novel live SARS-CoV-2 flow-cytometry based micro-neutralisation test (Micro-NT) was calibrated and validated using WHO SARS-CoV-2 IgG standards and showed comparable neutralisation titres to PRNT. We show a high reproducibility of the assay and a broad dynamic range of neutralisation titres across a COVID-19 convalescent cohort. Finally, Micro-NT can immune escape of VOCs (Beta and Omicron-BA.5) compared to WT SARS-CoV-2 using the same plasma samples.

159 **Results**

Here we aimed to develop a medium-throughput, rapid-turnaround live-virus Neutralisation Assay, to 160 161 enable screening of large clinical cohorts for COVID-19 vaccine studies, COVID-19 trials for convalescent plasma therapy, or monoclonal antibody studies. The assay involves 5 steps (Figure 1). 162 163 Firstly, serum from convalescent or vaccinated individuals is heat inactivated and serially diluted. 164 Secondly, the antibody dilutions are co-incubated with live SARS-CoV-2 (viral neutralisation). Thirdly, the virus/antibody mixture is used to infect cells in culture. Next, cells are trypsinised and fixed, 165 followed by intracellular staining and flow cytometry. Finally, the data is analysed to find the 166 Neutralisation Titre resulting in a 50% inhibition of infection (NT50). The NT50 can then be used to 167 168 easily compare the neutralisation capacities of human plasma between individuals, before or after 169 vaccination, or against different SARS-CoV-2 variants.

170 1. Flow Cytometry-Based Micro-NT Workflow

Step 1: Plasma is heat inactivated for 30 mins at 37°C. This ensures inactivation of the complement system which can trigger cytolysis. For clinical trials, or when multiple experiments are planned per sample, after heat-inactivation the plasma can be aliquoted and stored at -80°C, to avoid multiple freezethaw events. Optional: prior to dilution, the samples can be filter-sterilised (0.25μ M filter). If working with low volumes, this can be done after diluting the serum 1/20 in Infection Medium, and then proceeding with a half-log serial dilution (Figure 1). Minimum volume required is 10ul plasma for a test against a single variant, or 30ul against 3 variants (See Box 1 on sample processing).

BOX 1: Maximising Sample Processing

Up to 12x96-well plates can be comfortably processed together where only the inner 60-wells of the plate are used, leaving the outer wells available to be filled with PBS, limiting evaporation from the wells, and avoiding the 'edge-effect'. The 96-well plate format allows for three samples to be run in parallel, in duplicate, on a single plate (Figure 1), with a total of 36 samples per day, or a single sample against three SARS-CoV-2 variants for a total of 12 samples per day.

Within 1 hour, 12 plasma samples can be serially diluted across 2x48-well plates, using a 300ul multi-184 185 channel pipette, and divided amongst 3x96-well plates for incubation with SARS-CoV-2. An adjustable tip spacing, 300ul multi-channel makes it easy to transfer from the 48-well format to the 96-well format. 186 187 The neutralisation takes one hour at 37°C 5% CO2. A second hour of hands-on time is then required 188 to replace the medium on the cells from culture medium to infection medium (100ul per well) and add 189 100ul virus/plasma to the cells. As these are incubated in 96-well plates, this can easily be done with a 190 standard or automated multi-channel pipette. This process takes 2-hrs for 12-plates. 191 Cells are trypsinised and transferred to round-bottom plates for fixation and staining. Transfer

- efficiency can be increased by using an electronic 1ml multi-channel pipette to serially dispense
 PBS/PFA across a full plate (Thermo Scientific #46300800). The percentage of infected cells is
 measured directly in 96-well plates through automatic flow-cytometric detection of intracellular SARSCoV-2 N protein. Resuspending the cells in 60ul flow running buffer results in a run-time of 60-80 mins
- 196 *per plate, depending on instrument settings.*

197 Step 2: For viral neutralisation, plasma dilutions are co-incubated with an equal volume (1:1) live 198 SARS-CoV-2 WT or VOCs for 1-hr at 37°C 5% CO₂, to facilitate antibody-virus interaction (Figure 1). Step 3: Antibody-virus mixture is then added to sub-confluent Vero E6 or Vero E6/TMPRSS2 cells in 199 200 96-well plates and the cells are incubated for 18-hrs in 37°C, 5% CO₂ (Fig 1.4). Controls include wells 201 with no virus and virus alone. The SARS-CoV-2 variants used are fully infectious, capable of completing full replication and re-infection cycles, through cell-to-cell contact and also through release 202 of infectious particles into the supernatant. 18-hrs is enough time for the cells to produce viral proteins 203 204 abundantly, allowing for easy distinction of infected and non-infected cells during analysis, while not 205 providing enough time for viral cytopathic effects to develop. This is important, as cells must be intact 206 for subsequent staining and flow-cytometry analysis. See Box 2 for full details of the infectious model.

207 BOX 2: SARS-CoV-2 Infectious Model

The assay was developed with Vero E6 cells or Vero E6/TMPRSS2 cells, as both express the ACE-2 208 209 receptor, are highly permissive to SARS-CoV-2, and are a standard cellular model for SARS-CoV-2 neutralisation assays (35-37). The cellular protease TMPRSS2 is a co-factor of SARS-CoV-2 entry 210 211 expressed at the cell surface and important for membrane fusion. Its expression in Vero E6 enhances 212 the rate of infection. Of note, amplification of SARS-CoV-2 on cells lacking the TMPRSS2 receptor can lead to a well-described cell-line adaption, whereby deletions or mutations in the furin-cleavage site, 213 214 of 15-30bp at the S1/S2 cleavage site, allows the virus to become TMPRSS2-independent, in as few as 215 two passages (38, 39). Furthermore, this deletion (Δ Furin) can be associated with reduced 216 neutralisation compared to viruses bearing an intact Spike sequence, possibly due to an increased 217 particle to PFU ratio, resulting in more particles per infectious dose (40).

When multiple SARS-CoV-2 variants are tested in parallel, the stock viruses are titrated to infect 30-40% of cells after 18-hrs, as measured by flow cytometry. This provides a large enough population of infected cells to observe the neutralisation of the virus across the plasma dilution series. Infection of the population saturates around 70% infected cells, and so infection in this range could bias the resulting neutralisation titre.

Step 4: At 18-hrs post-infection, and following trypsinisation, the cells are resuspended in PBS with a 223 224 final concentration of 4% Formaldehyde to facilitate cell fixation and viral inactivation following an 225 incubation of 8-hrs in the dark. Cells should be processed as soon as possible but can be stored in 226 Formaldehyde for up to 24-hrs in the dark at room temperature. In instances where immediate 227 processing is not possible, formaldehyde should be replaced with PBS and plates can be stored at 4°C 228 in the dark for up to one week, although this is not recommended. Once the virus is inactivated, the 229 plates can be transferred to Containment Level 2 facilities to be permeabilised and stained for 230 intracellular SARS-CoV-2 nucleoprotein (NP). Flow cytometry is then used to measure NP positive 231 cells, as a percentage of the total gated live, single-cell population for each well (Figure 1). The gating strategy is described in detail in Box 3. 232

BOX 3: Flow Cytometry Staining and Analysis Strategy

Here we use intracellular SARS-CoV-2 N as our target protein. As N is more conserved than Spike (41), 234 235 the same antibody can be used to detect WT-B, WT-B.177.18, Beta and Omicron-BA.5 variants. 236 Furthermore, as N is the most abundantly expressed SARS-CoV-2 protein, it can be detected as soon 237 as 6-hrs post-infection and is clearly distinguishable from uninfected cells by 18-hrs post-infection. 238 Furthermore, there is no homology to cellular proteins that might result in high background staining. 239 Gating cells by Side Scatter (SSC) which indicates granularity, and Forward Scatter (FSC) which 240 indicates size, allows viable cells to be distinguished from dead cells (low FSC, typical SSC) and 241 cellular debris (low FSC and low SSC). Single cells can be separated from doublets or clumped cells 242 by gating the FSC-Area against FSC-Height, which should be a linear relationship. We can then plot 243 the live, single cells against FITC, which is the channel used to detect NP staining. Using our negative control wells (cells cultured in Infection Medium only, no virus) we gate to the immediate right of the 244 cell population. As these cells should not contain any NP, <1% of cells should be considered positive. 245 246 The same gate should then be applied to all wells. The positive controls (virus in Infection Medium, no 247 plasma) should be checked to ensure there has been an appropriate level of infection.

Step 5: Flow cytometry data can be exported as a CSV file for data analysis (Figure 1). Mean and
standard deviation can be calculated for each well. Wells where there are <1000 live, single events do

not have enough cells to be representative of the population and should be removed from the analysis.
Background level in the negative control wells should be subtracted from all the readings. The data can
then be presented as a percentage of inhibition of infection, where the negative controls have 100%
inhibition, and the positive controls have 0% inhibition. The NT50 can then be determined by a fourparameter non-linear regression.

255

2. Micro-NT produced comparable Neutralisation Titres to PRNT

We compared the NT50 values obtained using Micro-NT and conventional PRNT, as this is the gold 256 257 standard viral neutralisation assay. We used WHO International Standard for anti-SARS-CoV-2 258 immunoglobulin (human), a pool of eleven human plasma samples from convalescent patients with Low, Medium, or High titre SARS-CoV-2 S IgG, intended as a calibrant for serological assays. The 259 neutralising capacity of the standards against WT-B SARS-CoV-2 on Vero E6 cells was measured using 260 261 conventional PRNT (Figure 2A) or Micro-NT (Figure 2B). Both assays were able to distinguish Low, 262 Medium, and High IgG titre standards based on their neutralising capacity. The NT50 values were determined for each standard and compared between assays. The NT50 for the low IgG standard was 263 264 very similar between the two assays 86 for PRNT, versus 62 with Micro-NT (Figure 2C). Both assays 265 produced the same NT50 with the Medium IgG standard (435 with PRNT and 431 with Micro-NT). 266 Both assays found a high NT50 with the High IgG standard, with Micro-NT showing greater separation 267 between the Medium and High Titre results than the PRNT assay (1144 with PRNT and 2962 with 268 Micro-NT). Interestingly, the fold change between the medium and high results with Micro-NT closely 269 reflected the fold change between the antibody potencies in IU/ml as provided by the WHO (7-fold 270 increase between medium and high IgGs using WHO NT50s and 6.9-fold increase using Micro-NT 271 NT50s).

272

3. Micro-NT has good inter-assay and intra-assay reproducibility

The Flow-Cytometry based Micro-NT assay reproducibility was determined by measuring Inter-Assay and Intra-assay variability. To determine the Intra-assay reproducibility, we ran 3 COVID-19 convalescent plasma samples, with a low, medium or high NT50, each with an 8-point, half-log serial dilution (Figure 3A-3C). Each dilution was tested in 6 replicate wells on the same plate and the mean

and standard deviation calculated. The mean standard deviation was 1.76% across all 3 plates, with a
range from 0.09% (mean infection 0.37%) to 3.57% (mean infection 49.2%), showing high intra-assay
reproducibility.

3 naïve and 9 COVID-19 convalescent plasma samples were analysed using Micro-NT to determine the NT50 (Figure 3D). Each sample was tested using technical duplicates, in two independent experiments. The NT50 was determined for each experiment. The Mean and Standard Deviation was determined for each sample, and the co-efficient of variation (CV) measured (Standard Deviation/Mean). The mean CV was 11.64%, which shows high inter-assay reproducibility (Supplementary Table 1). The naive samples displayed no neutralising capacity (NT50<20).</p>

286

4. Micro-NT has a broad Dynamic Range

Across 190 convalescent plasma samples tested, we have found a broad range distribution of neutralising capacities, from 1 to >5000, without saturating the assay. The lower Limit of Detection (LOD) of the assay is an NT50 of 20, corresponding to the initial antibody dilution. Any sample unable to achieve a minimum of 50% inhibition with the initial dilution is given an arbitrary NT50 of 1. An 8point, half-log dilution from 1/20, to 1/62927, provides an optimal range for measuring neutralising capacity against SARS-CoV-2 from convalescent (Figure 4A-4D) or vaccinated (data not shown) plasma samples.

294

295

5. Micro-NT can be used to Measure Modulation in Neutralising Capacity against SARS-CoV-2 Variants of Concern

296 To examine whether Micro-NT can identify and characterise immune-escape SARS-CoV-2 VOCs, we 297 used the WHO SARS-CoV-2 IgG Standards in parallel to neutralise WT-B.177.18 SARS-CoV-2, and 298 two VOCs, Beta and Omicron-BA.5 on Vero E6/TMPRSS2 cells (Figure 5A-C). When neutralised with 299 Low IgG, WT-B.177.18 was the only variant neutralised (NT50 of 98.72), while neutralisation of Beta and Omicron-BA.5 was undetectable (Figure 5D). With Medium Titre IgG, all variants were neutralised 300 (NT50s of 192.1, 31.94 and 31.38 respectively), though with a 6-fold decrease in capacity against Beta 301 and Omicron-BA.5 compared to WT-B.177.18. With High Titre IgG, WT-B.177.18 remained the most 302 effectively neutralised, with an NT50 of 919.7, while Beta and Omicron-BA.5 remained poorly 303

neutralised with a 4.5-fold decrease seen with Beta (NT50 of 203.4) and a 7.3-fold decrease seen with
Omicron-BA.5 (NT50 of 125.4).

This flow-cytometry based Micro-NT is a medium throughput, reproducible, live SARS-CoV-2 assay,
comparable to PRNT but suitable for screening large clinical cohorts for NAbs against SARS-CoV-2
variants

309 Conclusion

Here we have introduced and presented in detail a new flow-cytometry-based Micro-Neutralisation Assay to quantify the neutralisation capacity of antibodies from plasma or serum. Live SARS-CoV-2 is neutralised by antibodies from convalescent/vaccinated plasma and then used to infect Vero-E6/Vero-E6/TMPRSS2 cells in a 96-well plate format. After 18-hrs, cells are trypsinised, fixed and stained for intra-cellular SARS-CoV-2 NP. Flow cytometry is then used to quantify the % of infected cells per condition, which allows determination of the NT50 for each plasma sample, against WT SARS-CoV-2 or VOCs.

This approach has been calibrated and validated against WHO SARS-CoV-2 IgG standards, using WT 317 and VOCs. Using WT-B SARS-CoV-2, we have shown comparable NT50 titres obtained using PRNT, 318 the gold standard for serological testing, and our flow-based Micro-NT, with the advantage of 319 significantly increased throughput. This assay is medium throughput, capable of processing 3 samples 320 per 96-well plate, with 12 plates being comfortably processed per day, simultaneously, for a total of 36-321 322 samples per day. The 18-hr infection duration is at the lowest end of the requirements for other micro-NTs (Table 1). Unlike CPE-based assays it directly measures infection through the detection of SARS-323 324 CoV-2 NP in infected cells, minimising risks of contamination or toxicity from serum/plasma being interpreted as viral-CPE. Similar to using well imagers to measure spot-forming units, flow cytometry 325 326 quantifies the infection in each well, meaning a dose-response curve can be plotted allowing determination of the NT50. 327

Flow cytometry has several advantages as an assay endpoint. Firstly, infection is quantifiable, being able to see the number of infected cells as well as the percentage of the whole population. This is in contrast to a technique such as RT-qPCR where normalisation against a house-keeping gene is required

331 to interpret the data, or a CPE-based approach, where wells can be scored as positive or negative, but not on a gradient. Secondly, the size and granularity of the cell population is measured, allowing issues 332 with viability or contamination to be quickly identified, that may not have been visible with a light 333 334 microscope. Thirdly, a flow cytometer with an automatic plate reader will process all wells without 335 requiring user input, other than set-up and cleaning, limiting hands-on processing time. Furthermore, as 336 cells are fixed prior to staining, flow analysis can take place in CL2 conditions, when compact flow 337 cytometers are placed within Biosafety Cabinets to control for risk of aerosol formation. This protocol 338 expands the option to perform live cell neutralising assays to those with flow-cytometry facilities, which 339 is becoming more common as labs are investing in this popular and diversely applicable technique. 340 However, as with all live virus assays, limitations include access to CL3 facilities, with trained staff to carry out live virus work. 341

While pseudovirus assays performed in CL2 conditions can address some of these limitations, livevirus assays remain the gold standard. New VOCs can be rapidly isolated from nasopharyngeal swabs, and once validated, can be used directly in the assay. By titrating the viruses to infect the same % of cells after 18-hrs, neutralisation capacity can be determined against several SARS-CoV-2 variants in parallel, without needing to account for differences in CPE, or duration of time to development of CPE. The assay is also appropriate for testing antibodies from a variety of sources, including serum, plasma, or commercial monoclonal antibodies.

349 Flexibility in SARS-CoV-2 variants and antibody sources means the assay is easily adapted to multiple applications. We have used the flow-based Micro-NT to define an RBD titre post-infection/vaccination 350 that correlates with a protective neutralisation titre (Kenny et al, in review) as well as to identify 351 352 COVID-19 convalescent individuals as donors for convalescent plasma therapy. Another use will be measuring functional antibody production post-vaccination. During initial COVID-19 vaccine clinical 353 354 trials, high infection and hospitalisation rates allowed for collection of data on protection from infection 355 or severe disease (42-45). Indeed, neutralisation titres post vaccination were found to be directly 356 correlated with vaccine efficacy (46). However, as vaccine uptake increases, and COVID-19 cases 357 decrease, such clinical endpoints are harder to achieve. Surrogate endpoints, including neutralisation

titres will therefore play an important role in measuring vaccine efficacy in next generation vaccine
trials (46, 47). VACCELERATE, an EU Consortium is currently co-ordinating clinical trials
identifying vaccine efficacy in elderly (ClinicalTrials.gov Identifier: NCT05160766) and paediatric
populations (EudraCT Number: 2021-005043-71) as well as the safety, timing, and efficacy of COVID19 booster vaccines in the fully vaccinated (EudraCT number 2021-004889-35). The flow-cytometry
based micro-neutralisation assay described here was chosen to enable the measurement of NAbs across
large numbers of clinical specimens (>400) across multiple SARS-CoV-2 variants.

365 Methods

366 Cells

Vero E6 (VERO C1008, Vero 76, clone E6, Vero E6), were obtained from ATCC (ATCC CRL-1587) 367 and maintained in Dulbecco's Modified Eagle's Medium (DMEM, Thermo Scientific, 61965-026) 368 369 supplemented with 10% Foetal Bovine Serum (Themo Scientific, 10500-064) (DMEM-10). Vero E6/TMPRSS2 cells (#100978), obtained from the Centre For AIDS Reagents (CFAR) at the National 370 371 Institute for Biological Standards and Control (NIBSC) (48) were cultured in DMEM supplemented with 10% Foetal Bovine Serum (FBS, DMEM-10) and Geneticin (Thermo Scientific, 10131035) at a 372 concentration of 1mg/ml, at 37°C in 5% CO2. All cell lines routinely tested negative for mycoplasma. 373 During the course of infection, cells were incubated in Complete Infection Medium, DMEM 2% FCS 374 (DMEM-2) supplemented with Penicillin (1U/ml) and Streptomycin (100ug/ml) (Sigma-Aldrich, 375 P4333) and amphotericin B (0.5ug/ml) (Thermo Fisher Scientific, 15290018) 376

377 Human Plasma samples

Plasma derived from ethylenediamintetraacetic acid (EDTA) anticoagulated whole blood was collected from COVID-19 RT-qPCR positive and negative participants of the All-Ireland Infectious Disease (AIID) Cohort (49). For this analysis we included either individuals with polymerase chain reaction (PCR)-confirmed COVID-19, documented vaccination with 2 doses of mRNA-1273, BNT162b2 or ChAdOx1-S, at least 14 days from the second dose, or individuals without COVID-19 or vaccination recruited with available bio-banked plasma dated no later than July 2019, prior to the onset of the COVID-19 pandemic. A total of 190 convalescent plasma samples from COVID-19 patients were tested

in this study. 11 non-COVID-19 plasma samples, collected prior to the COVID-19 pandemic and
negative for anti-SARS-CoV-2 antibodies were included as negative controls. Samples were stored at 80°C before use. All human plasma samples were heat-inactivated at 56°C for 30 minutes before testing.
First WHO International Standard for anti-SARS-CoV-2 immunoglobulin, human (NIBSC code:
20/136) is a pool of eleven human plasma from convalescent patients and was established in December
2020 by the WHO Expert Committee on Biological Standardization.

391 SARS-CoV-2 clinical isolates

All work with live SARS-CoV-2 was carried out in Containment Level 3 laboratory under Biosafety 392 393 Level 3 guidelines. WT Spike, Pango lineage B (WT-B) SARS-CoV-2 clinical isolate 2019-nCoV/Italy-INMI1, Clade V, Passage 4 (50) was obtained from the European Virus Archive goes Global (EVAg, 394 Spallanzani Institute, Rome) and following its amplification on Vero E6 cells (Passage 6) contained a 395 396 deletion in the Furin cleavage site. WT SARS-CoV-2 with D614G substitution (Pango lineage B.177.18 397 (WT-B.177.18), GenBank accession ON350866, Passage 2), Beta (Pango lineage B.1.351, GenBank accession ON350868, Passage 2) and Omicron (Pango lineage BA.5 (Omicron-BA.5), GenBank 398 399 accession OP508004, Passage 1) clinical isolates were isolated from SARS-CoV-2 positive 400 nasopharyngeal swabs from the AIID cohort. Supernatant was filter sterilised (0.2nm filter) and diluted 401 1:1 with Complete Infection Medium. Confluent Vero E6/TMPRSS2 cells were incubated with the 402 virus in a T12.5 flask until 50% cell death was observed using a light microscope. The supernatant and 403 cells were transferred to a confluent T175, with Complete Infection Medium. Cells were cultured until 404 50% cell death was observed. The supernatant was collected and centrifuged at 4000xg for 5 minutes, 405 aliquoted and stored at -80°C. The titre of the virus stocks was determined by median Tissue Culture 406 Infectious Dose assay (TCID50) and/or plaque assay. Viral RNA was isolated using Qiagen Viral 407 mRNA mini-kit according to manufacturer instructions. Viral RNA genome was sequenced to confirm 408 the integrity of the Spike protein in each variant and lineage. Viral genomes were quantified by RT-409 qPCR amplification of the SARS-CoV-2 Nucleoprotein (N2) gene (RNA diluted 1 in 10 in nuclease-410 free water resulted in Ct values of 19.5, 21.1 and 20.1 for WT-B.177.18, Beta and Omicron-BA.5

411 variants, respectively. WT-B.177.18 had a titre of 2.6x10⁶ PFU per ml, Beta had a titre of 1.2x10⁶

- 412 PFU/ml and Omicron-BA.5 had a titre of 2.2x10⁶ PFU/ml.
- 413 Flow Cytometry-Based Micro-Neutralisation Assay
- 414 Viral Neutralisation

415 Heat-inactivated plasma samples were diluted with a half-log, 8-point serial dilution, from a starting

416 dilution of 1 in 20 in Complete Infection Medium. SARS-CoV-2 isolates were titrated to infect 30-40%

417 of Vero E6/Vero E6/TMPRSS2 cells 18-hr post infection as determined by flow cytometry analyses of

418 SARS-CoV-2 Nucleoprotein positive cells. Viral isolates were diluted in Complete Infection Medium

419 and co-incubated with the plasma dilutions in a 1:1 ratio for 1 hour at 37° C, 5% CO₂.

420 Infection

421 Vero E6 or Vero E6/TMPRSS2 cells were plated (2.5×10^4) the day before use in 100ul Culture Medium,

422 in clear flat-bottom 96-well plates (Sarstedt, 83.3924). The cells were incubated overnight at 37°C 5%

423 CO₂ to reach 90-100% confluency at time of infection. Post-neutralisation, supernatant was removed
424 from the cells and replaced with 100ul Infection Medium and 100ul virus/plasma mix, in triplicates or

425 duplicates. Positive controls (Virus alone) and Negative controls (Infection Medium alone) were
426 included in each plate. Cells were incubated for 18 hours at 37°C 5% CO₂.

427 Cell collection

428 Supernatant was discarded and cells were rinsed with 100ul PBS. 25ul Trypsin-EDTA (Gibco, # 429 25300054) was added to the cells at 37°C until single-cell suspension was obtained. Cells were 430 resuspended in 75ul PBS and transferred to a round-bottom 96-well plate (Sarstedt, 83.3925500) with 431 100ul 8% formaldehyde solution (Sigma Aldrich, F8775) to achieve a final concentration of 4%. Cells 432 were fixed in the dark at room temperature for a minimum of 8 hours.

433 Cell Staining

All steps-post fixation were carried out in Biosafety Level 2 laboratory in Class 2 Biosafety Cabinets.
All centrifugation was carried out at 4000xg for 5 minutes (Heraeus Megafuge 16R, Thermo Scientific),

with 96-well plates contained within sealed buckets (Thermo Scientific, #75003625). The supernatant
was removed, and cells were permeabilised with Perm/Wash Buffer (BD, 554723) according to
manufacturer's instructions, which was maintained throughout antibody staining. Intracellular SARSCoV-2 Nucleoprotein (NP) staining was performed with SARS/SARS-CoV-2 Nucleocapsid
Monoclonal Antibody (E16C) (1/100 dilution, Invitrogen, MA1-7403), goat anti-mouse IgG2b-FITC
(1/500 dilution, Santa Cruz Biotechnology, SC-2080).

442 Flow Cytometry

Cells were resuspended in 60ul PBS-EDTA-2% for flow cytometry analysis (Beckman Coulter CytoFlex or CytoFlex S). Forward and Side-Scatter gates were used to exclude debris from intact cells.
Cells were then gated using Forward Scatter Area where single cells were gated based on linearity between Area and Height, excluding doublets. % Infected cells of the single cell population were determined using the negative control wells to set the boundary of the negatively staining populating in the FITC-channel (Blue 488nm laser, 525/40 filter). Gating was performed using CytExpert software (version 2.4.0.28, Beckman Coulter).

450 Analysis

Wells with <1000 single events were excluded from analysis. Positive controls (virus only, no plasma) had to be >20% and <70% infected while negative controls (Infection Medium only) had to be <3% or the plate would be excluded from analysis. The mean % infected cells for each plasma dilution was calculated, and this result was normalised using the control wells, where 0% viral inhibition was equal to the positive control and 100% viral inhibition was equal to the negative control. The plasma dilution resulting in a 50% reduction in infection (NT50) was determined using logistical regression (4paramater, variable slope) with GraphPad Prism (Version 9.3.1).

458 Plaque Reduction Neutralisation Test (PRNT)

Vero E6 cells were plated (4.2x10⁵) in 1ml DMEM-10 in clear flat-bottom 12-well plates. The cells
were incubated overnight at 37°C 5% CO₂ to reach 100% confluency at time of infection. WHO SARSCoV-2 IgG Standards with Low, Medium and High Titre IgG were diluted with a half-log, 8-point serial

462 dilution, from a starting dilution of 1 in 20 in Compete Infection Medium. SARS-CoV-2 (WT-B) was diluted in Complete Infection Medium to a concentration of 100 Plaque Forming Units (PFU) per 100ul 463 464 and co-incubated with the WHO standard dilutions in a 1:1 ratio for 1 hour at 37°C 5% CO₂. Supernatant 465 was removed from the cells and 200ul plasma/virus was added to each well. Plate was gently shaken to 466 ensure the surface of the well was evenly coated. The plates were incubated at 37°C 5% CO₂ for 90 mins, with shaking every 10 mins. 2ml Complete Infection Medium with 1% carboxycellulose (CMC, 467 468 Sigma #C5013) was added to each well. The plates were incubated for 96-hours until plaques became 469 visible. 2ml 8% formaldehyde solution was added directly to each well to a final concentration of 4% 470 and the plates were fixed for a minimum of 8 hours in the dark at room temperature. The supernatant 471 was removed from the cells and the cells washed 3 times in ddH₂O until all CMC was removed. Crystal violet (Sigma-Aldrich, #HT90132) 0.5% was added to just cover the surface of the well, incubated for 472 15 mins at room temperature, then removed with 2 washes in ddH₂O. Plates were allowed to fully dry 473 474 before being photographed. A modified ImageJ script (51) was used to count the plaques per well and the duplicates were averaged and normalised to the positive control (virus only). The % inhibition per 475 476 dilution was analysed with a non-linear regression (variable slope) on GraphPad Prism to determine the NT50. 477

478 Acknowledgements

SOR is the recipient of the Irish Research Council (IRC) Government of Ireland Postgraduate Scholarship (GOIPG/2019/4432). This study was supported by Science Foundation Ireland (20/COV/0305) and VACCELERATE, the European Corona Vaccine Trial Accelerator Platform. GK is funded through a fellowship from the United States Embassy in Ireland. The authors wish to thank all study participants and their families for their participation and support in the conduct of the All-Ireland Infectious Diseases Cohort Study.

485 The work has been performed with contribution or support of VACCELERATE participants.

486 The All-Ireland Infectious Diseases Cohort Study Investigators: Mater Misericordiae University

487 Hospital: A. Cotter, E. Muldoon, G. Sheehan, T. McGinty, JS. Lambert, S. Green, K. Leamy. St

488 Vincent's University Hospital: G. Kenny, K. McCann, R. McCann, C. O'Broin, S. Waqas, S. Savinelli,

489 E. Feeney, PWG. Mallon. CEPHR: A. Garcia Leon, S. Miles, D. Alalwan, R. Negi. Beaumont Hospital:

- 490 E. de Barra, S. McConkey, K. Hurley, I. Sulaiman. University College Cork: M. Horgan, C. Sadlier, J.
- 491 Eustace. University College Dublin: C. Kelly, T. Bracken. Sligo University Hospital: B. Whelan, Our
- 492 Lady of Lourdes Hospital: J Low. Wexford General Hospital: O Yousif. University Hospital Galway:
- 493 B. McNicholas. St Luke's Hospital Kilkenny: G. Courtney. Children's Health Ireland: P. Gavin.



494

495 Figure 1: SARS-CoV-2 Flow Based Micro-Neutralisation Assay Workflow. 1. Heat inactivated (30 mins at 56°C) human plasma samples are serially diluted (8-point, half-log from 1/20) in Infection 496 Medium, in 48-well plates. 2. Viral neutralisation is done in 96-well plates, where each antibody dilution 497 498 is co-incubated with WT SARS-CoV-2 or a Variant of Concern (VOC) for 60 mins at 37C. 3. Infection of sub-confluent Vero-E6 or Vero-E6/TMPRSS2 cells with antibody-virus mixture is carried out in 96-499 500 well plates for 18-hrs at 37C. Each plate can test one plasma sample against 3 SARS-CoV-2 variants in parallel, in duplicates, including controls (Virus alone and Infection Medium alone). 4. Cells are 501 trypsinised, fixed (4% formaldehyde for 8-hrs at room temperature), permeabilised and stained for 502 intracellular SARS-CoV-2 Nucleoprotein (NP). Infection is measured using Flow Cytometry, first 503 504 gating the live, single cell population, and then NP negative and positive populations. 5. Flow cytometry 505 data is analysed to determine the % of infected (NP+) cells per well and then the % of inhibition can be determined by normalising each dilution to the positive and negative controls. NT50 can be determined 506 507 from the inhibition curve, as the dilution factor resulting in 50% inhibition of infection. Created with BioRender.com 508



509 Figure 2: Validation of Flow-Based Micro-NT using WHO International SARS-CoV-2 IgG Standards 510 511 (A-B) SARS-CoV-2 (WT-B) was neutralised for 1 hour with an 8-point, half-log serial dilution of WHO 512 SARS-CoV-2 Low, Medium or High Titre IgG. (A) The antibody-virus mixture was then plated onto Vero E6 cells for 90 mins before overlay (1% CMC) was added and incubated for 96-hours. Plaques 513 were quantified and the inhibition of infection is presented as a percentage, relative to the virus-only 514 515 control wells. Graph shows the mean and standard deviation of duplicates (n=1). (B) In parallel, the virus-antibody mixture was added onto Vero E6 cells for 18-hrs before cells were trypsinised, fixed and 516 517 permeabilised, and stained for the SARS-CoV-2 NP. % of infected cells was determined by flow 518 cytometry analysis. Inhibition of infection is presented as percentage, relative to the virus-only control 519 wells. Graph shows the mean and standard deviation of duplicates (n=1). (C) Table shows the potency of Neutralising antibodies present in WHO International SARS-CoV-2 IgG Standards with Low, 520 521 Medium and High titre IgG in International Units (IU/ml) as determined by the WHO. NT50 values 522 were determined for each standard by running in parallel on PRNT and Micro-NT, against SARS-CoV-2 (WT-B) on Vero E6 cells. NT50 was determined using the percentage of inhibition for each dilution 523 factor, relative to the virus-only control and calculated from a non-linear regression (variable slope) 524

with Graph Pad Prism equal to the 50% Inhibitory Dilution (ID50). 525





Figure 3: Flow Cytometry-Based Micro-NT Intra- and Inter-Assay Variation (A-C) Data shows the % 527 528 infection across 8 dilutions of convalescent sera with (A) low, (B) mid, or (C) high neutralising capacity 529 against WT-B.177.18 SARS-CoV-2 on Vero E6/TMPRSS2 cells. Each dilution was tested in 6 wells 530 on a single plate, and the % infected cells in each well is shown. (D) NT50 values for 12 convalescent serum samples against WT-B.177.18 SARS-CoV-2 were analysed using Micro-NT. Each dilution was 531 532 tested in duplicate, and each sample was run twice, independently. NT50 was determined using the percentage of inhibition for each dilution factor, relative to the virus-only control and calculated from 533 534 a non-linear regression (variable slope) with Graph Pad Prism equal to the 50% Inhibitory Dilution 535 (ID50). Graph shows the NT50 values obtained for each sample (n=2).



536

- 537 Figure 4: Dynamic Range of Flow Cytometry-Based Micro-NT We analysed the NT50s of 190 COVID-
- 19 naïve or convalescent plasma samples, using Micro-NT, against SARS-CoV-2 (WT-B) on Vero E6 538
- for 18-hrs. (A-D) Graphs show neutralising capacity of 3 convalescent plasma samples (P1-P3) across 539
- 8-point, half-log serial dilution, representative of samples with 50% Neutralisation Titres (NT50) within 540
- 541 a similar range. The percentage of viral inhibition of each dilution was calculated relative to the virus 542 only control. (E) Plasma from COVID-19 naïve individuals showed little or no neutralisation capacity
- against SARS-CoV-2. (F) Graph shows all the NT50 values obtained across the cohort of COVID-19 543
- convalescent plasma samples, measured using Micro-NT. 544



D.

Antibody Titre	NT50 (WT-B.177.18)	NT50 (Beta)	NT50 (Omicron-BA.5)
Low	98.72	1	1
Medium	192.1	31.94	31.38
High	919.7	203.4	125.4

545

546 Figure 5: Comparison of SARS-CoV-2 IgG Standards tested against SARS-CoV-2 Variants SARS-CoV-2 WT-B.177.18, Beta and Omicron-BA.5 were neutralised for 1 hour with an 8-point, half-log 547 serial dilution of WHO SARS-CoV-2 (A) Low, (B) Medium or (C) High Titre IgG. The viruses were 548 plated onto Vero E6/TMPRSS2 cells for 18-hrs before cells were trypsinised, fixed and permeabilised, 549 and stained for the SARS-CoV-2 NP. % of infected cells was determined by flow cytometry analysis. 550 551 Inhibition of infection is presented as percentage, relative to the virus-only control wells. Graph shows 552 the mean and standard deviation of duplicates (n=1). (D) shows the NT50 values obtained for the WHO International SARS-CoV-2 IgG Standards with Low, Medium and High titre IgG when run against WT-553 B.177.18 SARS-CoV-2, and VOCs Beta and Omicron-BA.5. NT50 was determined using the 554 555 percentage of inhibition for each dilution factor, relative to the virus-only control and calculated from a non-linear regression (variable slope) with Graph Pad Prism equal to the 50% Inhibitory Dilution 556 557 (ID50).

558

NT50 (Rep 1)	NT50 (Rep 2)	NT50 (mean)	St. Dev	% CV
0	0	0	0	0.00%
0	0	0	0	0.00%
0	0	0	0	0.00%
65.37	51.64	58.505	6.865	11.73%
74.04	77.47	75.755	1.715	2.26%
116.4	76.22	96.31	20.09	20.86%
129	158.5	143.75	14.75	10.26%
372.7	333.8	353.25	19.45	5.51%
302.2	636.5	469.35	167.15	35.61%
376.3	785	580.65	204.35	35.19%
1426	1637	1531.5	105.5	6.89%
3089	3653	3371	282	8.37%
			Mean	11.39%

559

Supplementary Table 1: Inter-Assay Co-efficient of Variation Table shows the NT50 values obtained 560 from 2 independent experiments of 12 convalescent COVID-19 plasma samples, as measured using 561

Micro-NT against D614G SARS-CoV-2. Co-efficient of Variation (CV) was calculated as Standard 562

Deviation (St. Dev)/Mean of Replicate 1 and 2 and displayed as a percentage. The % CV between plates 563

564 is the average CV of all samples tested.

565

References 566

567 Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev 1. 568 Microbiol. 2021;19(3):141-54.

569 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real 2. time. Lancet Infect Dis. 2020;20(5):533-4. 570

571 Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F. Antibody-mediated 3. neutralization of SARS-CoV-2. Immunity. 2022;55(6):925-44. 572

573 Li K, Huang B, Wu M, Zhong A, Li L, Cai Y, et al. Dynamic changes in anti-SARS-CoV-2 4. 574 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun. 575 2020;11(1):6044.

576 Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation 5. and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in 577 humans. Nat Microbiol. 2020;5(12):1598-607. 578

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing 579 6. 580 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. 581 Nat Med. 2021;27(7):1205-11.

582 Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, 7. Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral 583 Variants. Front Immunol. 2021;12:701501. 584

585 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and 8. Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-92.e6. 586

Yi C, Sun X, Ling Z, Sun B. Jigsaw puzzle of SARS-CoV-2 RBD evolution and immune 587 9. 588 escape. Cell Mol Immunol. 2022;19(7):848-51.

Yuan M, Huang D, Lee CD, Wu NC, Jackson AM, Zhu X, et al. Structural and functional 589 10. 590 ramifications of antigenic drift in recent SARS-CoV-2 variants. Science. 2021;373(6556):818-23.

Wang C, van Haperen R, Gutiérrez-Álvarez J, Li W, Okba NMA, Albulescu I, et al. A 591 11. 592 conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by crossreactive monoclonal antibodies. Nature Communications. 2021;12(1):1-15. 593

Rössler A, Knabl L, von Laer D, Kimpel J. Neutralization Profile after Recovery from SARS-594 12. 595 CoV-2 Omicron Infection. N Engl J Med. 3862022. p. 1764-6.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.18.23284713; this version posted January 18, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Kenny G, Negi R, O'Reilly S, Garcia-Leon A, Alalwan D, Gaillard CM, et al. Performance and
validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection
or vaccination. J Immunol Methods. 2022:113345.

599 14. Shim SM, Kim JW, Jung S, Jung Y, Woo HM, Yang JS, et al. Persistence of the neutralizing
600 antibody response after SARS-CoV-2 infection. Clin Microbiol Infect. 2022;28(4):614.e1-.e4.

Edara VV, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, et al. Infection and
Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N Engl J
Med. 3852021. p. 664-6.

604 16. Sheward DJ, Kim C, Ehling RA, Pankow A, Castro Dopico X, Dyrdak R, et al. Neutralisation
605 sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. Lancet Infect Dis.
606 2022;22(6):813-20.

Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, et al. Increased memory
B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 2022;607(7917):128-34.

Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, et al. Neutralizing antibody
responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by
breakthrough infection. Sci Transl Med. 2022;14(637):eabn8057.

Bruel T, Pinaud L, Tondeur L, Planas D, Staropoli I, Porrot F, et al. Neutralising antibody
responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of
BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study. EClinicalMedicine.

615 2022;51:101576.

616 20. Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Convalescent plasma
617 for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine.
618 2021;27(11):2012-24.

Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al. Early Outpatient
Treatment for Covid-19 with Convalescent Plasma. N Engl J Med. 2022;386(18):1700-11.

621 22. Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al. Escape of SARS-CoV-2
622 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593(7857):142-6.

623 23. Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, et al. SARS-CoV-2
624 Omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol.
625 2022;7(8):1161-79.

Bewley KR, Coombes NS, Gagnon L, McInroy L, Baker N, Shaik I, et al. Quantification of
SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization
and pseudotyped virus neutralization assays. Nature Protocols. 2021;16(6):3114-40.

629 25. Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E, et al.
630 Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2
631 Neutralizing Antibodies. Curr Protoc Immunol. 2020;131(1):e116.

632 26. Abidi SH, Imtiaz K, Kanji A, Qaiser S, Khan E, Iqbal K, et al. A rapid real-time polymerase
633 chain reaction-based live virus microneutralization assay for detection of neutralizing antibodies against
634 SARS-CoV-2 in blood/serum. PLoS One. 2021;16(12):e0259551.

635 27. Lichtenegger S, Saiger S, Hardt M, Kulnik S, Wagner GE, Kleinhappl B, et al. Development
636 of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout. J Clin Microbiol.
637 2022;60(7):e0037622.

638 28. Frische A, Brooks PT, Gybel-Brask M, Sækmose SG, Jensen BA, Mikkelsen S, et al.
639 Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay. PLoS One.
640 2022;17(7):e0272298.

641 29. Manenti A, Maggetti M, Casa E, Martinuzzi D, Torelli A, Trombetta CM, et al. Evaluation of

642 SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization
 643 assay in human serum samples. J Med Virol. 2020;92(10):2096-104.

James J, Rhodes S, Ross CS, Skinner P, Smith SP, Shipley R, et al. Comparison of Serological
 Assays for the Detection of SARS-CoV-2 Antibodies. Viruses. 2021;13(4).

Tea F, Ospina Stella A, Aggarwal A, Ross Darley D, Pilli D, Vitale D, et al. SARS-CoV-2
neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. PLoS Med.
2021;18(7):e1003656.

Sie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Quantification of SARS-CoV-2 neutralizing
antibody by a pseudotyped virus-based assay. Nat Protoc. 2020;15(11):3699-715.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.18.23284713; this version posted January 18, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 651 33. Servellita V, Syed AM, Morris MK, Brazer N, Saldhi P, Garcia-Knight M, et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell. 652 653 2022;185(9):1539-48.e5.
- 654 34. Saker K, Pozzetto B, Escuret V, Pitiot V, Massardier-Pilonchéry A, Mokdad B, et al. Evaluation 655 of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects. J Clin Virol. 2022;152:105169. 656
- 657 Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, et al. A longitudinal study of 35. 658 SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-
- 659 19 severity. Cell Mol Immunol. 2021;18(2):318-27.
- Muena NA, García-Salum T, Pardo-Roa C, Avendaño MJ, Serrano EF, Levican J, et al. 660 36. 661 Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and 662 previously infected individuals. EBioMedicine. 2022;78:103972.
- 663 37. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced 664 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184(16):4220-665 36.e13.
- 666 Sasaki M, Uemura K, Sato A, Toba S, Sanaki T, Maenaka K, et al. SARS-CoV-2 variants with 38. 667 mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells. PLoS Pathog. 2021;17(1):e1009233. 668
- Lau SY, Wang P, Mok BW, Zhang AJ, Chu H, Lee AC, et al. Attenuated SARS-CoV-2 variants 669 39. with deletions at the S1/S2 junction. Emerg Microbes Infect. 2020;9(1):837-42. 670
- 671 Johnson B, Xie X, Bailey A, Kalveram B, Lokugamage K, Muruato A, et al. Loss of furin 40. cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021;591(7849). 672
- Bai Z, Cao Y, Liu W, Li J. The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral 673 41. 674 Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses. 675 2021;13(6).
- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of 676 42. the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16. 677
- 678 43. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and 679 Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-680 201.
- 681 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy 44. 682 of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
- 683 45. Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 Safety and 684 Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021;385(25):2348-60. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune 685 46.
- 686 correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 687 2022;375(6576):43-50.
- 688 47. Falsey AR, Frenck RW, Jr., Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-CoV-2 689 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med. 3852021. p. 1627-9.
- Nao N, Sato K, Yamagishi J, Tahara M, Nakatsu Y, Seki F, et al. Consensus and variations in 690 48. 691 cell line specificity among human metapneumovirus strains. PLoS One. 2019;14(4):e0215822.
- 49. Mallon PWG, Tinago W, Leon AG, McCann K, Kenny G, McGettrick P, et al. Dynamic 692 693 Change and Clinical Relevance of Postinfectious SARS-CoV-2 Antibody Responses. Open Forum 694 Infect Dis. 2021;8(8):ofab122.
- 695 50. Capobianchi MR, Rueca M, Messina F, Giombini E, Carletti F, Colavita F, et al. Molecular 696 characterization of SARS-CoV-2 from the first case of COVID-19 in Italy. Clin Microbiol Infect. 697 2020;26(7):954-6.
- Cacciabue M, Currá A, Gismondi MI. ViralPlaque: a Fiji macro for automated assessment of 698 51. 699 viral plaque statistics. PeerJ. 2019;7:e7729.

700